Reply to: “Cutaneous squamous cell carcinoma progression during imiquimod treatment”

To the Editor: We appreciate the observation made by Dika et  al about cutaneous squamous cell carcinoma (cSCC) progression during imiquimod treatment.1 These cases emphasize what we describe in part II of our continuing medical education (CME) article–that topical chemotherapy agents should be limited to the treatment of actinic keratoses and squamous cel l carcinoma in situ and are only Food and Drug Administration–approved for use on actinic keratoses.2 As stated in the CME article, our preferred treatment choice for widespread actinic damage is topical 5-fluorouracil, as imiquimod is not practical for application on large surface areas and can l ead to cytokine release when applied to a broad area.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Tags: JAAD online Source Type: research